Company News in the Life Science Industry

»

Reset 

Kanazawa University Research: Lipids and Proteins: Further Evidence for Functional Crosstalk in Cells

KANAZAWA, Japan, June 17, 2018 /PRNewswire/ --

Read more ››
By: PR Newswire Association LLC. - 17 Jun 2018

Aprea Therapeutics Presents Results From Phase Ib/II Clinical Study of APR-246 and Azacitidine (AZA) in Patients with TP53 Mutant Myelodysplastic Syndromes (MDS) at the 2018 European Hematology Association (EHA) Annual Meeting in Stockholm

BOSTON and STOCKHOLM, June 17, 2018 /PRNewswire/ -- Aprea Therapeutics presented results at the 2018 EHA Annual Meeting from its Phase Ib/II clinical study in MDS. The ongoing study is evaluating the safety and efficacy of APR-246 in combination with azacitidine for the treatment of TP53... Read more ››

By: PR Newswire Association LLC. - 17 Jun 2018
Related companies:  Aprea Therapeutics AB

Cytokinetics Announces Data From Phase 2 Clinical Study of Reldesemtiv in Patients With Spinal Muscular Atrophy Presented at the 2018 Annual Cure SMA Conference

Read more ››
By: Nasdaq / GlobenewsWire - 16 Jun 2018
Related companies:  Cytokinetics, Inc.

Updated Preliminary Data from SMA FIREFISH Program in Type 1 Babies Presented at the CureSMA Conference

SOUTH PLAINFIELD, N.J., June 16, 2018 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the presentation of updated interim clinical data from Part 1 of the FIREFISH study investigating risdiplam (RG7916) in babies with Type 1 Spinal Muscular Atrophy (SMA), at the... Read more ››

By: PR Newswire Association LLC. - 16 Jun 2018
Related companies:  PTC Therapeutics, Inc.

'Build a Bond' - A Himalaya Companion Care Initiative to Drive Pet Adoption

BENGALURU, India, June 16, 2018 /PRNewswire/ --

Read more ››
By: PR Newswire Association LLC. - 16 Jun 2018

Phase 3 QuANTUM-R Study Demonstrates Daiichi Sankyo's Quizartinib Significantly Prolongs Overall Survival as Single Agent Compared to Chemotherapy in Patients with Relapsed/Refractory AML with FLT3-ITD Mutations

TOKOYO, MUNICH, and BASKING RIDGE, N.J., June 16, 2018 /PRNewswire/ -- Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) announced that positive results from the pivotal QuANTUM-R phase 3 study of single agent quizartinib were presented today as a late-breaking oral presentation in... Read more ››

By: PR Newswire Association LLC. - 16 Jun 2018

Dr. Toby Cosgrove of Cleveland Clinic Joins RxRevu Board

DENVER, June 16, 2018 /PRNewswire-iReach/ -- RxRevu, the industry leader in Prescription Decision Support, is proud to announce that Dr. Toby M. Cosgrove has joined their Board of Directors.

Read more ››
By: PR Newswire Association LLC. - 16 Jun 2018

ZEISS unveils next generation of ophthalmic laser VISULAS green at World Ophthalmology Congress

VISULAS(®) green, the next generation of photocoagulation laser from ZEISS allows doctors to fully concentrate on the patient's treatment procedure without interruption.

Read more ››
By: PR Newswire Association LLC. - 16 Jun 2018

European Hematology Association: iNNOVATE Study: Ibrutinib Plus Rituximab for Patients With Waldenström's Macroglobulinemia

STOCKHOLM, June 16, 2018 /PRNewswire/ --

Read more ››
By: PR Newswire Association LLC. - 16 Jun 2018

European Hematology Association: Answering the Unmet Need in One of the Most Common Types of Lymphoma: It's as Simple as A-D-C

STOCKHOLM, June 16, 2018 /PRNewswire/ --

Read more ››
By: PR Newswire Association LLC. - 16 Jun 2018

SOPHiA GENETICS Acquires Interactive Biosoftware to Drive Growth and Accelerate Data-Driven Medicine Adoption Around the World

MILAN, June 16, 2018 /PRNewswire/ --

Read more ››
By: PR Newswire Association LLC. - 16 Jun 2018

European Hematology Association: A New Anti-CD22 CAR-T Immunotherapy Saved Life of Children With Leukemia

STOCKHOLM, June 16, 2018 /PRNewswire/ --

Read more ››
By: PR Newswire Association LLC. - 16 Jun 2018

Novartis JULIET trial of Kymriah demonstrates more than one-year durability of responses in adults with relapsed or refractory DLBCL

EAST HANOVER, N.J., June 16, 2018 /PRNewswire/ -- Novartis today announced 14-month results from the pivotal JULIET clinical trial showing ongoing durable responses are achievable with Kymriah(®) (tisagenlecleucel) when administered to adult patients with relapsed or refractory (r/r) diffuse... Read more ››

By: PR Newswire Association LLC. - 16 Jun 2018
Related companies:  Genomics Institute of the Novartis Research Foundation

Precipio Inc. Announces Adjournment of Annual Meeting of Shareholders

Read more ››
By: Nasdaq / GlobenewsWire - 16 Jun 2018
Related companies:  Precipio Diagnostics

Alberta Business Community Raises $640,000 for 2018 CEO Rescue in the Rockies for STARS Fundraiser

Read more ››
By: Nasdaq / GlobenewsWire - 16 Jun 2018

Indivior Is Granted Temporary Restraining Order

SLOUGH, England, June 15, 2018 /PRNewswire/ -- Indivior PLC (LON: INDV) ("Indivior" or the "Company") today announced that the U.S. District Court for the District of New Jersey has granted Indivior a temporary restraining order (TRO) that compels Dr. Reddy's (DRL) to immediately cease its launch... Read more ››

By: PR Newswire Association LLC. - 16 Jun 2018
Related companies:  Dr. Reddy's Laboratories (UK) Ltd | Indivior UK Limited

Study Showcases how Medical Affairs Provides Value to External Stakeholders Such as Payers and Specialty Pharmacies

CHAPEL HILL, N.C., June 15, 2018 /PRNewswire/ -- Medical Affairs has long been a key function within the pharmaceutical industry because of its role in providing medical information to external stakeholder groups.

Read more ››
By: PR Newswire Association LLC. - 16 Jun 2018

Global Creatinine Measurement 2018-2023: Commercialization of Advanced Testing Methods Presents Market Opportunities

DUBLIN, June 15, 2018 /PRNewswire/ --

Read more ››
By: PR Newswire Association LLC. - 16 Jun 2018

Global Cosmetic Antioxidants Market Forecast to 2023: Market is Driven by a Rise in Aging Population, Increasing Disposable Income, and Changing Lifestyle

DUBLIN, June 15, 2018 /PRNewswire/ --

Read more ››
By: PR Newswire Association LLC. - 16 Jun 2018

ObsEva SA to Hold Investor Call to Announce Topline Results of the EDELWEISS Phase 2b Clinical Trial of Linzagolix (OBE2109) in Women with Endometriosis-Associated Pain on Monday June 18, 2018

Read more ››
By: Nasdaq / GlobenewsWire - 15 Jun 2018
Related companies:  ObsEva SA
1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25 »

Explore our database of over 50,000 companies